Icône BioRender

Enterocyte (epithelial���mesenchymal transition, stage 3)

Enterocyte (epithelial–mesenchymal transition, stage 3) - Editable icon of a spindle-shaped mesenchymal cell that is undergoing epithelial-mesenchymal transition, stage 3 of 4

[{"image":"https://icons.cdn.biorender.com/w75xh75/5ca75b9a1177743300099887/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ca75b9a1177743300099887/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5ca75b9a1177743300099885/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5ca75b9a1177743300099885/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23f8/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23f8/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23f9/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23f9/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23fa/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23fa/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23fb/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23fb/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23fc/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23fc/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23fd/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23fd/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23fe/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23fe/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d23ff/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d23ff/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2400/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2400/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2401/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2401/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2402/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2402/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2403/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2403/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2404/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2404/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2405/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2405/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2406/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2406/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2407/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2407/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2408/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2408/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2409/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2409/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240a/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240a/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240b/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240b/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240c/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240c/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240d/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240d/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240e/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240e/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d240f/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d240f/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2410/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2410/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2411/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2411/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2412/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2412/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2413/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2413/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2414/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2414/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2415/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2415/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2416/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2416/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2417/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2417/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2418/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2418/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2419/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2419/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241a/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241a/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241b/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241b/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241c/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241c/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241d/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241d/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241e/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241e/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d241f/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d241f/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2420/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2420/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2421/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2421/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2422/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2422/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2423/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2423/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2424/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2424/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2425/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2425/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2426/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2426/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2427/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2427/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2428/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2428/5ca75b70117774330009987e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66d74f6cc5a4ff7a190d2429/5ca75b70117774330009987e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66d74f6cc5a4ff7a190d2429/5ca75b70117774330009987e.png"}]

Utiliser cette icône – Gratuit
Aucune carte de crédit requise pour l'inscription.

Cette icône est entièrement modifiable dans BioRender

  • Ajoutez du texte, des formes et d'autres icônes
  • Recherchez parmi plus de 50 000 icônes scientifiquement exactes
  • Changez les couleurs et réorganisez chaque icône, ligne et étiquette
  • Exportez ou partagez pour tout type d'utilisation
Scientist Avatars

Rejoignez plus de 4 millions de scientifiques qui créent déjà des figures prêtes à être publiées

Passez des icônes à la figure terminée – en quelques minutes

  • Rechercher à partir de plus de 50 000 icônes scientifiquement exactes et évaluées par des pairs
  • Personnalisez avec des étiquettes, des formes et des icônes supplémentaires – tout est entièrement modifiable
  • Exporter ou partagez vos figures avec vos collaborateurs
    ‍

Ce n'est pas tout à fait l'icône qu'il vous faut ? Découvrez-en plus.

Recherchez parmi plus de 50 000 icônes dans plus de 30 domaines des sciences de la vie.

search icon
arrow-right

intestine,gi,gastrointestinal,intestinal,enterocyte,columnar cell,ciliated,epithelial cell,mesenchymal cell,stem cell,healing,wound,fibrosis,metastasis,cancer,epithelial,mesenchymal,EMT,transition,epithelial to mesenchymal transition,oncology

Voir plus

Essayez un synonyme, ou inscrivez-vous pour demander une icône depuis l'application.

Types d'images

Enterocyte (epithelial���mesenchymal transition, stage 3) icon JPEG

Enterocyte (epithelial���mesenchymal transition, stage 3) icon PNG

Enterocyte (epithelial���mesenchymal transition, stage 3) icon SVG

Enterocyte (epithelial���mesenchymal transition, stage 3) icon GIF

FAQ sur les icônes BioRender

How are scientists using the Enterocyte (epithelial���mesenchymal transition, stage 3) icon in their work?

BioRender users often use the Enterocyte (epithelial���mesenchymal transition, stage 3) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Puis-je utiliser cette icône dans une figure ou une illustration scientifique BioRender ?

Yes, the Enterocyte (epithelial���mesenchymal transition, stage 3) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Enterocyte (epithelial���mesenchymal transition, stage 3) icon customizable in BioRender?

Most icons in BioRender, including the Enterocyte (epithelial���mesenchymal transition, stage 3) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Enterocyte (epithelial���mesenchymal transition, stage 3) icon for publication or presentations?

Yes, figures containing the Enterocyte (epithelial���mesenchymal transition, stage 3) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Enterocyte (epithelial���mesenchymal transition, stage 3) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Enterocyte (epithelial���mesenchymal transition, stage 3) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

Qu'est-ce que BioRender ?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Enterocyte (epithelial���mesenchymal transition, stage 3) icon along with our library of more than 30,000 life science icons.

Utiliser cette icône dans BioRender

Créez dès aujourd'hui des illustrations scientifiques professionnelles
antibody elements3D Phospholipid illustration

Vous recherchez du contenu scientifique ?

Parcourez plus de 50 000 icônes et modèles validés par des pairs, faciles à utiliser et gratuits.

Trouvez le vôtre dès maintenant
x icon